Company Quick10K Filing
Guided Therapeutics
10-Q 2021-03-31 Filed 2021-05-21
10-K 2020-12-31 Filed 2021-04-07
10-Q 2020-09-30 Filed 2020-11-05
S-1 2020-09-10 Public Filing
10-Q 2020-06-30 Filed 2020-08-20
10-Q 2020-03-31 Filed 2020-07-07
10-K 2019-12-31 Filed 2020-04-20
10-Q 2019-09-30 Filed 2020-03-09
10-Q 2019-06-30 Filed 2020-02-11
10-Q 2019-03-31 Filed 2019-07-11
10-K 2018-12-31 Filed 2019-05-08
10-Q 2018-09-30 Filed 2018-11-14
10-Q 2018-06-30 Filed 2018-08-14
S-1 2018-06-14 Public Filing
10-Q 2018-03-31 Filed 2018-05-21
10-K 2017-12-31 Filed 2018-04-17
10-Q 2017-09-30 Filed 2017-11-20
10-Q 2017-06-30 Filed 2017-08-18
10-Q 2017-03-31 Filed 2017-05-22
10-K 2016-12-31 Filed 2017-03-22
10-Q 2016-09-30 Filed 2016-12-05
10-Q 2016-06-30 Filed 2016-08-17
10-Q 2016-03-31 Filed 2016-05-19
10-K 2015-12-31 Filed 2016-03-15
10-Q 2015-09-30 Filed 2015-11-12
10-Q 2015-06-30 Filed 2015-08-13
10-Q 2015-03-31 Filed 2015-05-13
10-K 2014-12-31 Filed 2015-03-25
10-Q 2014-09-30 Filed 2014-11-12
10-Q 2014-06-30 Filed 2014-08-13
10-Q 2014-03-31 Filed 2014-05-15
10-K 2013-12-31 Filed 2014-03-26
10-Q 2013-09-30 Filed 2013-11-13
10-Q 2013-06-30 Filed 2013-08-14
10-Q 2013-03-31 Filed 2013-05-14
10-K 2012-12-31 Filed 2013-03-27
10-Q 2012-09-30 Filed 2012-11-13
10-Q 2012-06-30 Filed 2012-08-14
10-Q 2012-03-31 Filed 2012-05-14
10-Q 2011-09-30 Filed 2011-11-14
10-Q 2011-06-30 Filed 2011-08-15
10-Q 2011-03-31 Filed 2011-05-16
10-K 2010-12-31 Filed 2011-03-30
10-Q 2010-09-30 Filed 2010-11-10
10-Q 2010-06-30 Filed 2010-08-12
10-Q 2010-03-31 Filed 2010-05-13
10-K 2009-12-31 Filed 2010-03-23
8-K 2020-09-16
8-K 2020-03-31
8-K 2020-03-31
8-K 2019-04-03
8-K 2018-11-14
8-K 2018-10-25
8-K 2018-08-31

Guided Therapeutics Financials

GTHP Metrics, Comps, Filings

Quarterly | Annual

Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Aries I Acquisition Corp. (RAMMU)
024 Pharma (EEIG)
Beauty Health Co (VSPRW)
Aquarius I Acquisition Corp. (AQUI)
MIZUHO FINANCIAL GROUP INC (MZHOF)
Eucrates Biomedical Acquisition Corp. (EUCRW)
11 Good Energy (ELVN)
180 Life Sciences Corp. (ATNFW)
1347 Capital Corp (TFSC)
Avanti Acquisition Corp. (AVAN-WT)
CORDIA CORP (CORG)
FCCC INC (FCIC)
Biofrontera Inc. (BFRI)
Ameren Illinois Co (AILNP)
MITSUBISHI UFJ FINANCIAL GROUP INC (MBFJF)
Janus International Group, Inc. (JBI-WT)
23andMe Holding Co. (MEUSW)
OceanTech Acquisitions I Corp. (OTECU)
Palayan Resources, Inc. (PLYN)
ALABAMA POWER CO (APRCP)

Balance Sheet ($'000)2011-06-302011-12-312012-03-312012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-31
Cash2,3432,2001,0042,6091,0451,1091,9804006135048542162181,9741723556224141874176417006
Accounts Receivable14911738651071661771121331222334173383582822191902302892260414035641313
Inventory461524439111,19311,1191,2041,1801,1499859121,1191,2531,2381,171773836756577265295280265114112
PP&E641,0331,0881,2702,2201,2631,1371,0302,3278078047062,4325154442,4352,4402,4402172,4412,4412,4412,4412,4412,4412,4412,4412,4412,4412,426
Assets3,3184,3103,0854,7713,4783,5854,3962,9313,3162,5963,8223,7223,0312,5604,0372,7672,5632,3662,3132,0601,4921,4921,508905489527418491236404
Accounts Payable9371,1028631,0407658789868228911,2681,0631,6641,7331,5631,9631,4661,8241,9772,2082,4502,6002,7482,8882,9653,0192,9762,9612,9713,0133,004
Long-Term Debt17404061,7232,6501359944001,33604795,068445
Liabilities2,9082,7332,1772,6472,3452,6502,4093,4233,8666,3167,6677,4967,5786,7746,2508,1257,8169,4499,37010,75810,54411,85513,25019,89118,46514,63614,66116,06016,413
Stockholders' Equity4101,5771,133-107-4,465-5,562-9,266-19,402-15,824
Income Statement ($'000)2011-06-302011-12-312012-03-312012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-31
Revenue9137186931,012167222863461911221315108903348218
Cost of Revenue7059991932251455108981199-5114144-239-194973101
Gross Profit-1213-26-3-59-164-70-703420-104-1362481949610-18955-64-228174217
R&D619714787830813860596499607635892666373305413387290148872089196698369634347
SG&A7791,0008641,3621,2031,4651,0711,0351,4211,6941,5491,5001,1351,2021,2971,4141,0348466027174284491,206420308461193227
Tax
Net Income-496-1,013-986-1,187-1,815-1,750-1,437-2,213-1,562-2,152-2,971-3,198-1,245-1,706-2,191-1,758130-1,879-211-2,010-107-969-2,365-7,1511,0826,866-743-215
Cash Flow ($'000)2011-06-302011-12-312012-03-312012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-31
Cash Operating-663-395-242-417-186
Cash Investing-130-56-1010-104-4-115-25-600-2-600
Cash Financing124411,4792,3311151,3064002,4151,5651,6024822,52459632297655048207394-123270590470207446192